Viral Oncolysates as Human Tumor Vaccines

References

• Marx J. L. Cancer vaccines show promise at last. Science 1989; 245: 813–815
   PubMedGoogle Scholar
• Editorial. TUmour cell vaccines: has their time arrived?. Lancet 1989; 2: 955–957
   PubMedGoogle Scholar
• Lindenmann J., Klein P. A. Immunological aspects of viral oncolysis, Recent Results in Cancer Research. Springer-Verlag, New York 1967; 1–84
   Google Scholar
• Koprowski H., Love R., Koprowska I. Enhancement of susceptibility to viruses in neoplastic tissues. Eleventh Annual Symposium on Fundamental Cancer Research. University of Texas M.D. Anderson Hospital and Tumor Institute, 1957; 111–128, Viruses and Tumor Growth
   Google Scholar
• Sinkovics J. G. Project M27/gm. Immunotherapy of cancer by immunization with cultured tumor cells. The University of Texas M.D. Anderson Hospital, Research Report, Printing Division, The University of Texas, Austin, Texas, Houston, Texas, 346–354,1968-70; 486–494,1972; 474–480,1974; 541–548,1976
   Google Scholar
• Sinkovics J. G., Project M27/gml3. Effect of oncolytic viruses in selected cases of human malignant diseases, Research Report, The University of Texas M.D. Anderson Hospital. Printing Division, The University of Texas, Austin, Texas, Houston, Texas, 348–349, 1968–70; 488–490,1972; 473–474, 1974; 533–536, 1976
   Google Scholar
• Sinkovics J. G., Improved response to conventional treatment and immune reactions to sarcoma antigens of patients with sarcomas, Discussion Remarks in Interaction of Radiation and Host Immune Defense Mechanisms in Malignancy, Brookhaven National Laboratory Report, 331–339, 1974
   Google Scholar
• Sinkovics J. G. A reappraisal of cytotoxic lymphocytes in human tumor immunology. Cancer Biology and Therapeutics, J. G. Cory, A. Szentivanyi. Plenum Press, New York, London 1987; 225–253
   Google Scholar
• Kay H. D., Sinkovics J. G. Cytotoxic lymphocytes from normal donors. Lancet 1974; 2: 296–297
   PubMed Web of Science ®Google Scholar
• Kay H. D., Sinkovics J. G. Project M30/gm21: An investigation into antitumor surveillance of normal individuals, Research Report, The University of Texas M.D. Anderson Hospital, Houston, Texas. Printing Division University of Texas, Austin, Texas, 562–564, 1976
   Google Scholar
• Herberman R. B., Reynolds C. W., Ortaldo J. R. Mechanism of cytotoxicity by natural killer (NK) cells. Ann. Rev. Immunol. 1986; 4: 651–680
   PubMed Web of Science ®Google Scholar
• Sinkovics J. G. Oncolytic viruses and viral oncolysates. Ann. Immunol. Hung. 1986; 26: 271–290
   Google Scholar
• Ackermann W. W., Kurtz H. A new host-virus system. Proc. Soc. Exp. Biol. Med. 1952; 81: 421–423
   PubMedGoogle Scholar
• Cassel W. A., Garrett R. E. Relationship between viral neurotropism and oncolysis I. Study of vaccinia virus. Cancer 1967; 20: 433–439
   PubMedGoogle Scholar
• Sinkovics J. G. Studies on the biological characteristics of the Newcastle disease virus (NDV) adapted to the brain of newborne mice. Archiv. ges. Virusforschung 1957; 4/7: 403–411
   Google Scholar
• Sinkovics J. G. Enhancement of carcinostatic activity of Newcastle disease virus (NDV) associated with adaptation of NDV to suckling mouse brain. Bacteriological Proc. 1957; 96, (Abstract #M108)
   Google Scholar
• Sinkovics J. G., Gyorkey F., Kusyk C., Siciliano M. Growth of human tumor cells in established cultures. Meth. Cancer Res. 1978; 14: 243–323
   Google Scholar
• Michael A. Chirigos, 1977; 28235–236
   Google Scholar
• Sinkovics J. G., Williams D. E., Campos L. T., Kay D. H., Romero J. J. Intensification of immune reactions of patients to cultured sarcoma cells: attempts at monitored immunotherapy. Semin. Oncol. 1974; 1: 351–365
   PubMedGoogle Scholar
• Sinkovics J. G., Thota H., Kay H. D., Loh K. K., Williams D. E., Howe C. D., Shullenberger C. C. Intensification of immune reactions by immunotherapy: attempts at measuring sarcoma-specific reactions in vitro. Neoplasm Immunity: Theory and Application, R. G. Crispen. University of Illinois Schori Press, Evanston, Ill 1974; 137–152
   Google Scholar
• Sinkovics J. G. Immunotherapy of sarcomas with viral oncolysates. J. Am. Med. Assoc. 1977; 237: 869
   PubMedGoogle Scholar
• Sinkovics J. G., Plager C., Romero J. Immunology and immunotherapy of patients with sarcomas, in 1977 Chicago Symposium. Immunotherapy of Solid Tumors, R. G. Crispen. The Franklin Institute Press, 1977; 211–219
   Google Scholar
• Sinkovics J. G., Plager C., McMurtrey M., Papadopoulos N. E., Waldinger R., Combs S., Romero J. J., Romsdahl M. M. Adjuvant chemoimmunotherapy for malignant melanoma. Neoplasm Immunity: Experimental and Clinical, R. G. Crispen. Elsevier North Holland, New York, Amsterdam 1980; 481–519
   Google Scholar
• Sinkovics J. G., Papadopoulos N. E., Plager C. Viral oncolysates for the immunotherapy of human tumors. Proceedings of the 10th International Symposium for Comparative Research on Leukemia and Related Diseases, D. S. Yohn, J. J. Blakeslee. Elsevier BioMed, New York, Amsterdam 1981; 613–615
   Google Scholar
• Cassel W. A., Murray D. R., Phillips H. S. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983; 52: 856–860
   PubMed Web of Science ®Google Scholar
• Cassel W. A., Murray D. R. Letter to the Editor. Nat. Immun. Cell Growth Regul. 1988; 7: 351–352
   PubMedGoogle Scholar
• Plager C., Bowen J. M., Fenoglio C., Papadopoulos N. E. J., Murray L., Chawla S. R., Benjamin R. S., Hersh E. M. Adjuvant immunotherapy with Newcastle disease virus oncolysate of M.D. Anderson (MDAH) stage III-B malignant melanoma. Proc. Am. Soc. Clin. Oncol. 1986; 5: 137, (Abstract #534)
   Google Scholar
• Cassel W. A., Murray D. R. Chapter 18, Viral oncolysate in the treatment of regional metastases of melanoma. Cancer in the Neck. Evaluation and Treatment. Macmillan, New York 1986; 235–242
   Google Scholar
• Freedman R. S., Bowen J. M., Herson J., Wharton J. T., Rutledge E. N., Hamberger A. D. Virusmodified homologous tumor-cell extract in the treatment of vulvar carcinoma. Cancer Immunol. Immuno-ther. 1980; 8: 33–38
   Google Scholar
• Freedman R. S., Bowen J. M., Herson J. H., Wharton J. T., Edwards C. L., Rutledge E. N. Immunotherapy for vulvar carcinoma with virus-modified homologous extracts. Obstet. Gynecol. 1983; 62: 707–714
   PubMedGoogle Scholar
• Freedman R. S., Bowen J. M., Lotzov S. E., Edwards C. L., Lewis E., Katz R. L. Chapter 11, Virus augmentation as a biologic-modifier approach: experience with intracavitary virus-augmentation therapy, Annual Clinical Conference on Cancer, The University of Texas System Cancer Center. Gynecological Cancer: Diagnosis and Treatment Strategies 1987; 29: 137–157
   Google Scholar
• Freedman R. S., Edwards C. L., Bowen J. M., Lotzov S. E., Katz R., Lewis E., Atkinson N., Carsetti R. Viral oncolysates in patients with advanced ovarian cancer. Gynecol. Oncol. 1988; 29: 337–347
   PubMed Web of Science ®Google Scholar
• Lotzová E., Savary C. A., Freedman R. S., Bowen J. M. Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract. Cancer Immunol. Immunother. 1984; 17: 124–129
   PubMed Web of Science ®Google Scholar
• Lotzová E. Therapeutic possibilities of virus-modified tumor cell extracts and interleukin-2 in human ovarian cancer. Nat. Immun. Cell Growth Regul. 1986; 5: 277–282
   PubMedGoogle Scholar
• Ioannides C. G., Platsoucas C. D., O'Brian C., Patenia R., Bowen J. M., Wharton J. T., Freedman R. S. Viral oncolysates in cancer treatment: immunological mechanisms of action (review). Anticancer Res. 1989; 9: 535–544
   PubMed Web of Science ®Google Scholar
• Ioannides C. G., Platsoucas C. D., Patenia R., Kim P. L., Bowen J. M., Morris M., Edwards C., Wharton J. T., Freedman R. S. T-cell functions in ovarian cancer patients treated with viral oncolysates: I. Increased helper activity to immunoglobulins production. Anticancer Res. 1990; 10: 645–654
   PubMed Web of Science ®Google Scholar
• Ioannides C. G., Platsoucas C. D., Freedman R. S. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates. In Vivo 1990; 4: 17–24
   PubMedGoogle Scholar
• Ioannides C. G., Freedman R. S., Platsoucas C. D., Rashed S., Kim Y. P. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J. Immunol. 1991; 146: 1700–1707
   PubMed Web of Science ®Google Scholar
• Green A. A., Pratt C., Webster R. G., Smith K. Immunotherapy of osteosarcoma patients with virus-modified tumor cells. Ann. NY Acad. Sci. 1976; 277: 396–411
   PubMedGoogle Scholar
• Sauter C., Lindenmann J., Gmür I., Berchtold P., Obrecht A. R., Senn H. J., Cavalli F. Viral oncolysate (VO) in the treatment of acute myelogenous leukemia (AML): analysis at 10 years. Proc. Am. Soc. Clin. Oncol. 1985; 4: 154, (Abstract #C-598)
   Google Scholar
• Wallack M. K., Steplewski Z., Koprowski H., Rosato E., George J., Hulihan B., Johnson J. A new approach in specific active immunotherapy. Cancer 1977; 39: 560–564
   PubMed Web of Science ®Google Scholar
• Hersey P., Edwards A., D'Alessandro G., MacDonald M. Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. Cancer Immunol. Immunother. 1986; 22: 221–231
   PubMedGoogle Scholar
• Hersey R., Edwards A., Coates A., Shaw H., McCarthy W., Milton G. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol. Immunother. 1987; 25: 257–265
   PubMedGoogle Scholar
• Wallack M. K. Specific immunotherapy with vaccinia oncolysates. Cancer Immunol. Immunother. 1981; 12: 1–4
   Google Scholar
• Bash J. A., Wallack M. K. Vaccinia virus oncolysates in the treatment of malignant melanoma. Malignant Melanoma: Biology, Diagnosis, and Therapy, L. Nathanson. Kluwer Academic Publishers, Boston 1988; 177–190
   Google Scholar
• Schirrmacher V., Hoegen R V., Schlag P., Liebrich W., Lehner B., Schumacher K., Ahlert T., Bastert G. Active specific immunotherapy with autologous tumor cell vaccines modified by Newcastle disease virus: experimental and clinical studies. Cancer Metastasis, V. Schirrmacher, R. Schwartz-Albiez. Springer-Verlag, Berlin, Heidelberg 1989; 155–170
   Google Scholar
• Schirrmacher V. Postoperative activation of tumor-specific T-cells as a means to achieve immune control of minimal residual disease, in General Motors Cancer Research Foundation Accomplishments. Cancer Research 1986. J.B. Lippincott, Philadelphia 1986; 218–232
   Google Scholar
• Bromberg J. S., Lake R., Brunswick W. Viral antigens act as helper determinants for antibody response to cell surface antigens. J. Immunol. 1982; 129: 683–688
   PubMedGoogle Scholar
• Boone C. M., Paranjpe M., Corme T., Gillette R. Virus-augmented tumor transplantation antigens. Int. J. Cancer 1974; 13: 543–551
   PubMedGoogle Scholar
• Shimizu T., Fujiwara H., Ueda S., Wakamiya N., Kato S., Hamaoka T. The augmentation of tumor specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus reactive helper T cells. Eur. J. Immunol. 1984; 14: 839–843
   PubMedGoogle Scholar
• Shimizu X., Zou J. -R., Ikegame K., Katagiri T., Fujiwara H., Hamaoka T. Evidence for the functional binding in vivo for tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts. J. Immunol. 1991; 146: 1703–1714
   Google Scholar
• Shohan J., Hirsch R., Zakay-Rones Z., Osband M. E., Brennert H. J. Augmentation of tumor cell immunogenicity by viruses–an approach to specific immunotherapy of cancer. Nat. Immun. Cell Growth Regul. 1990; 9: 165–172
   PubMedGoogle Scholar
• Sinkovics J. G. An explanation for “postoncolytic immunity” induced by oncolytic viruses and viral oncolysates. Vlllth International Congress of Virology, Berlin, August, 26–311990, 246, (Abstract #P69–025)
   Google Scholar
• Freedman R. S., Bowen J. M., Atkinson E. N., Scott W., Wagner S. Virus-augmented delayed hypersensitivity skin tests in gynecological malignancies. Cancer Immunol. Immunother. 1984; 17: 142–146
   PubMedGoogle Scholar
• Lotzová E., Herberman R. B. Reassessment of LAK phenomenology: a review. Nat. Immun. Cell Growth Regul 1987; 6: 109–115
   PubMedGoogle Scholar
• Lotzová E., Savary C. A., Freedman R. S., Edwards C. L., Morris M. Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype. Cancer Immunol. Immunother. 1990; 31: 169–175
   PubMedGoogle Scholar
• Blanchard D. K., Kavanagh J. J., Sinkovics J. G., Cavanagh D., Hewitt S. M., Djeu J. Y. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients. Cancer Res. 1988; 48: 6321–6327
   PubMed Web of Science ®Google Scholar
• Duke R. C., Persechini P. M., Chang S., Liu C-C., Cohen J. J., Young J. D. -E. Purified perforin induces target cell lysis but not DNA fragmentation. J. Exp. Med. 1989; 170: 1451–1456
   PubMed Web of Science ®Google Scholar
• Podack E. R. Granule-mediated cytolysis of target cells, Cytotoxic Effector Mechanisms, Current Topics in Microbiology and Immunology 140, 1–9 Podack E. R. eds Berlin, Heidelberg: Springer-Verlag, 1988
   Google Scholar
• Stanley K., Luzio P. Perforin, a family of killer proteins. Nature 1988; 334: 475–476
   PubMedGoogle Scholar
• Podack E. R., Olsen K. J., Lowrey D. M., Lichtenheld M. Structure and function of perforin, Current Topics in Microbiology and Immunology. Springer-Verlag, Berlin, Heidelberg 1988; 140: 11–17
   Google Scholar
• Lichtenheld M. G., Olsen I., Lu R., Lowrey D. M., Hameed A., Hengartner H., Podack E. R. Structure and function of human perforin. Nature 1988; 335: 448–451
   PubMed Web of Science ®Google Scholar
• Shinkai Y., Takio K., Okumura K. Homology of perforin to the ninth component of complement (C9). Nature 1988; 334: 525–527
   PubMed Web of Science ®Google Scholar
• Acha-Orbea H., Scarpellino L., Hertig S., Dupuis M., Tschopp J. Inhibition of lymphocyte mediated cytotoxicity by perforin antisense oligonucleotides. EMBO J. 1990; 9: 3815–3819
   PubMedGoogle Scholar
• Sasaki A., Melder R. J., Whiteside T. L., Herberman R. B., Jain R. K. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J. Natl. Cancer Inst. 1991; 83: 433–437
   PubMed Web of Science ®Google Scholar
• Lotzova E. Role of human circulating and tumor-infiltrating lymphocytes in cancer defense and treatment. Nat. Immun. Cell Growth Regul. 1990; 9: 253–264
   PubMedGoogle Scholar
• Nagler-Anderson C., Lichtenheld M., Eisen H. N., Podack E. R. Perforin mRNA in primary peritoneal exudate cytotoxic T lymphocytes. J. Immunol. 1989; 143: 3440–3443
   PubMedGoogle Scholar
• Jenne D. E., Tschopp J. Granzymes: a family of serine proteases in granules of cytolytic T lymphocytes. Current Topics in Microbiology and Immunology. Springer-Verlag, Berlin, Heidelberg 1988; 140: 33–47
   Google Scholar
• Eisen H. N., Verret C. R., Firmenich A. A., Kranz D. M. Resistance of cytolytic T lymphocytes to the lytic components they release. 17th Forum in Immunology, Ann. Inst. Pasteur/Immunol. Elsevier, Paris 1987; 138: 328–331
   Google Scholar
• Paul N. L., Ruddle N. H. Lymphotoxin. Ann. Rev. Immunol. 1988; 6: 407–438
   PubMed Web of Science ®Google Scholar
• Sato T., Sato N., Takahashi S., Koshiba H., Kikuchi K. Specific cytotoxicity of long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res. 1986; 46: 4384–4389
   PubMedGoogle Scholar
• Kuppner M. C., Harnou M. E., de Tribolet N. Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res. 1988; 48: 6926–6932
   PubMed Web of Science ®Google Scholar
• Van den Eynde B., Hainaut R., Herin Knuth A., Lemoine C., Weynants R., van der Bruggen P., Fauchet R., Boon T. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer 1989; 44: 634–640
   PubMedGoogle Scholar
• Anichini A., Mazzocchi A., Fossati G., Parmiani G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J. Immunol. 1989; 142: 3692–3701
   PubMed Web of Science ®Google Scholar
• Knuth A., Wolfel T., Klehmann E., Boon X., Meyer zum Biischenfelde K. -H. Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection. Proc. Natl. Acad. Sci. USA 1989; 86: 2804–2808
   PubMed Web of Science ®Google Scholar
• Whiteside X. L., Heo D. S., Takagi S., Johnson J. T., Iwatsuki S., Herberman R. B. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol. Immunother. 1988; 26: 1–10
   PubMed Web of Science ®Google Scholar
• Belldegrun A., Muul L. M., Rosenberg S. A. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 1988; 48: 206–214
   PubMed Web of Science ®Google Scholar
• Vánky E., Klein E. Auto-tumor lysis by blood lymphocytes in vitro. Strongly activated lymphocytes lack selectivity. Immunotherapy 1989; 125–132
   Google Scholar
• Allavena P., Presti R. L., Bello M. D., Lucchini V., Lissoni A., Zanetta G., Mangioni C., Mantovani A. Proliferative response of ovarian cancer patients to autologous tumor cells. Cancer Immunol. Immunother. 1988; 27: 69–76
   PubMedGoogle Scholar
• Ortaldo J. R., Wiltrout R. H. Implications of potential positive correlation between autologous tumor-cell-killing activity and prognosis in lung cancer. J. Natl. Cancer Inst. 1990; 82: 1663–1665
   PubMedGoogle Scholar
• Vanky F., Klein E., Willems J., Book K., Ivert T., Peterffy A., Nilsonne U., Kreicbergs A. Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture–No correlation with the postsurgical clinical course. Cancer Immunol. Immunother. 1987; 24: 180–183
   PubMed Web of Science ®Google Scholar
• Sinkovics J. G., Dreyer D. A., Shirato E., Cabiness J. R., Shullenberger C. C. Cytotoxic lymphocytes. I. Destruction of neoplastic cells by lymphocytes of human origin. Texas Rep. Biol. Med. 1971; 29: 227–272
   PubMedGoogle Scholar
• Wang C. -H., Sinkovics J. G., Kay H. D., Gyorkey E., Shullenberger C. Growth of permanent lymphoid cell cultures from human source: tenth anniversary. Texas Rep. Biol. Med. 1975; 33: 213–250
   PubMedGoogle Scholar
• Plate J. M., Lukaszewska T. L., Bustamante G., Hayes R. L. Cytokines involved in the generation of cytolytic effector T lymphocytes. Ann. NY Acad. Sci. 1988; 532: 149–157
   PubMedGoogle Scholar
• Maraskovsky E., Chen W. -E., Shortman K. IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J. Immunol. 1989; 143: 1210–1214
   PubMed Web of Science ®Google Scholar
• Westly H. J., Kleiss A. J., Kelley K. W., Wong P. K. Y., Yuen R-H. Newcastle disease virus-infected splenocytes express the proopiomelanocortin gene. J. Exp. Med. 1986; 163: 1589–1594
   PubMed Web of Science ®Google Scholar
• Lorence R. M., Rood P. A., Kelley K. W. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-a and augmentation of its cytotoxicity. J. Natl. Cancer Inst. 1988; 80: 1305–1312
   PubMed Web of Science ®Google Scholar
• Blalock J. E., Smith E. M. Human lymphocyte production of corticotropin and endorphin-like substances: Association with leukocyte interferon. Proc. Natl. Acad. Sci. USA 1981; 78: 7530–7534
   PubMedGoogle Scholar
• Kikuchi Y., Kita T., Nagata I. Effects of opioid peptides on the cellular immunity in spleen cells from intact nude mice or nude mice bearing human ovarian carcinoma. Cancer Immunol. Immunother. 1990; 30: 374–376
   PubMedGoogle Scholar
• Goldfeld A. E., Doyle C., Maniatis T. Human tumor necrosis factor a gene regulation by virus and lipopolysaccharide. Proc. Natl. Acad. Sci. USA 1990; 87: 9769–9773
   PubMed Web of Science ®Google Scholar
• Krönke M., Hensel G., Schlüter C., Scheurich R., Schütze, Pfizenmaier K. Tumor ne'crosis factor and lymphotoxin expression in human tumor cell lines. Cancer Res. 1988; 48: 5417–5421
   PubMedGoogle Scholar
• Pak C. C., Fidler I. J. Activated macrophages distinguish undifferentiated-tumorigenic from differenti-ated-nontumorigenic murine erythroleukemia cells. Differentiation 1989; 41: 49–55
   PubMedGoogle Scholar
• Grimm E. A., Crump W. L., Durett A., Hester J. P., Lago-Deenadalayan S., Owen-Schaub L. B. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol. Immunother. 1988; 27: 53–58
   PubMed Web of Science ®Google Scholar
• Kuppner M. C., Hamou M. -F., Bodmer S., Fontana A., de Tribolet N. The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int. J. Cancer 1988; 42: 562–567
   PubMed Web of Science ®Google Scholar
• Mulé J. J., Schwarz S. L., Roberts A. B., Sporn M. B., Rosenberg S. A. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol. Immunother. 1988; 26: 95–100
   PubMed Web of Science ®Google Scholar
• Bodmer S., Strommer K., Frei K., Siepl C., de Tribolet N., Heid I., Fontana A. Immunosuppression and transforming growth factor-B in glioblastoma. J. Immunol. 1989; 143: 3222–3229
   PubMed Web of Science ®Google Scholar
• Fontana A., Frei K., Bodmer S., Hofer E., Schreier M. H., Palladino M. A., Jr., Zinkernagel R. M. Transforming growth factor-B inhibits the generation of cytotoxic T cells in virus-infected mice. J. Immunol. 1989; 143: 3230–3234
   PubMed Web of Science ®Google Scholar
• Hirte H., Clark D. A. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-B as a suppressive factor. Cancer Immunol. Immunother. 1991; 32: 296–302
   PubMed Web of Science ®Google Scholar
• Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-β. Nature 1988; 334: 360–362
   Google Scholar
• Sinkovics J. G., Cabiness J. R., Shullenberger C. C. Monitoring in vitro of immune reactions to solid tumors. Front. Radiat. Ther. Oncol. 1972; 7: 99–119
   Google Scholar
• Sinkovics J. G., Campos L. T., Loh K. K., Cormia E., Velasquez W., Shullenberger C. C. (1976) Chemoimmunotherapy for three categories of solid tumors (sarcoma, melanoma, lymphoma): the problem of immunoresistant tumors. Neoplasm Immunity: Mechanisms, Proceedings of a Chicago Symposium. 1975, R. G. Crispen. ITR Publisher, Chicago, 193–212
   Google Scholar
• Ucker D. S. Cytotoxic T lymphocytes and glucocorticoids activate an endogenous suicide process in target cells. Nature 1987; 327: 62–64
   PubMed Web of Science ®Google Scholar
• Gromkowski S. H., Brown T. C., Masson D., Tschopp J. Lack of DNA degradation in target cells lysed by granules derived from cytolytic T lymphocytes. J. Immunol. 1988; 141: 774–778
   PubMedGoogle Scholar
• Zychlinsky A., Zheing L. M., Liu C-C., Young J. D.-E. Cytolytic lymphocytes induce both apoptosis and necrosis in target cells. J, Immunol. 1991; 146: 393–400
   PubMed Web of Science ®Google Scholar
• Duke R. C., Chervenak R., Cohen J. J. Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc. Natl. Acad. Sci. USA 1983; 80: 6361–6365
   PubMed Web of Science ®Google Scholar
• Romero J. J., Campos L. T., Sinkovics J. G. Complement-fixing cytolytic antibodies in human sera directed against established human tumor cell lines. Clinical Research January, 1976; 24/1: 32A, (Abstract)
   Google Scholar
• Livingston P. O., Albino A. P., Chung T. J., Real E. X., Houghton A. N., Oettgen H. E., Old L. J. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 1985; 135: 713–720
   Google Scholar
• Wallack M. K., Bash J. A., Leftheriotis E., Seigler H., Bland K., Wanebo H., Balch C., Bartolucci A. A. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch. Surg. 1987; 122: 1460–1463
   PubMed Web of Science ®Google Scholar
• Savage H. E., Rossen R. D., Hersh E. M., Freedman R. S., Bowen J. M., Plager C. Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. Cancer Res. 1986; 46: 2127–2133
   PubMedGoogle Scholar
• Schuepbach J., Sauter C. Inverse correlation of antiviral antibody titers and the remission length in patients treated with viral oncolysate: a possible new prognostic sign in acute myelogenous leukemia. Cancer 1981; 48: 1363–1367
   PubMedGoogle Scholar
• Debatin K. -M., Goldmann C. K., Bamford R., Waldmann T. A., Krammer E. H. Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet 1990; 335: 497–500
   PubMed Web of Science ®Google Scholar
• Christiaansen J. E., Sears D. W. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies. Cancer Res. 1984; 44: 3712–3718
   PubMed Web of Science ®Google Scholar
• Wettendorff M., Iliopoulos D., Tempero M., Kay H. D., DeFreitas E., Koprowski H., Herlyn D. Idiotypic cascades in cancer patients treated with monoclonal antibody CO17–1A. Proc. Natl. Acad. Sci. USA 1989; 86: 3787–3791
   PubMedGoogle Scholar
• Loibner H., Plot R., Rot A., Werner G., Wrann M., Samonigg H., Schmid M., Stoger H., Truschnig M., Herlyn D., Koprowski H. Immunoreactivity of patient with colorectal cancer metastasis after immunisation with anti-idiotypes. Lancet 1990; 335: 171
   PubMed Web of Science ®Google Scholar
• Goodnow C. C., Adelstein S., Basten A. The need for central and peripheral tolerance in the B cell repertoire. Science 1990; 248: 1373–1379
   PubMed Web of Science ®Google Scholar
• Murphy K. M., Heimberger A. B., Loh D. Y. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCR10 thymocytes, in vivo. Science 1990; 250: 1720–1723
   PubMed Web of Science ®Google Scholar
• Eaton M. D., Almquist S. J. P. Tumor immunity and autoimmunity produced by injection of antigens modified by adsorbed virus. Cancer Immunol. Immunother. 1980; 9: 199–205
   Google Scholar
• Anomasiri W. T., Tovell D. R., Tyrrell D. L. J. Paramyxovirus membrane protein enhances antibody production to new antigenic determinants in the actin molecule: a model for virus-induced autoimmunity. J. Virology 1990; 64: 3179–3184
   PubMedGoogle Scholar
• Krah D. L., Chappin P. W. Mice immunized with measles virus develop antibodies to a cell surface receptor for binding virus. J. Virol. 1988; 62: 1565–1572
   PubMedGoogle Scholar
• Chantler J. K., Tingle A. K., Petty R. E. Persistent rubella virus infection associated with chronic arthritis in children. N. Engl. J. Med. 1985; 313: 1117–1123
   PubMed Web of Science ®Google Scholar
• Whitton J. L. Lymphocytic choriomeningitis virus CTL. Semin. Virology 1990; 1: 257–262
   Google Scholar
• Lehmann-Grube E., Koskophidis D., Lohler J. Recovery from acute virus infection. Role of cytotoxic T lymphocytes in the elimination of lymphocytic choriomeningitis virus from spleens of mice. Ann. NY Acad. Sci. 1988; 532: 239–255
   Google Scholar
• Sinkovics J. G. Virus neutralisation experiments with lymphoid cell- and lymph node-extracts. Acta Microbiologica Hungarica 1955; 2: 385–400
   Google Scholar
• Sinkovics J. G., Molnár E. Az ellenanyagképzés specifikus bénulása lymphocyteás choriomeningitis-virussal fertözött egerekben (Specific paralysis of antibody production in mice infected with lymphocytic choriomeningitis virus). KisMetes Orvostudomdny 1955; 6: 647–653
   Google Scholar
• Herlyn M., Menrad A., Koprowski H. Structure, function, and clinical significance of human tumor antigens. J. Natl. Cancer Inst. 1990; 82: 1883–1889
   PubMed Web of Science ®Google Scholar
• Pena X., Alonso C., Solana R., Serrano R., Carracedo J., Ramirez R. Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur. J. Immunol. 1990; 20: 2445–2449
   PubMedGoogle Scholar
• Crowley N. X., Darrow T. L., Quinn-Allen M. A., Seigler H. E. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. J. Immunol. 1991; 146: 1692–1699
   PubMed Web of Science ®Google Scholar
• Sinkovics X. G. Oncogenes-antioncogenes and virus therapy of cancer. Anticancer Res. 1989; 9: 1281–1290
   PubMedGoogle Scholar
• Ostrang-Rosenberg S., Thakur A., Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 1990; 144: 4068–4071
   PubMedGoogle Scholar
• Itaya T., Yamagiwa S., Okada E., Oikawa T., Kuzumaki N., Takeichi N., Hosokawa M., Kobayashi H. Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld)l. Cancer Res. 1987; 47: 3136–3140
   PubMed Web of Science ®Google Scholar
• Fearon E. R., Itaya T., Hunt B., Vogelstein B., Frost P. Induction in a murine tumor of immunogenic variants by transfection with a foreign gene. Cancer Res. 1988; 48: 2975–2978
   PubMedGoogle Scholar
• Vánky E., Stuber G., Rotstein S., Klein E. Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells. Cancer Immunol. Immunother. 1989; 28: 17–21
   PubMedGoogle Scholar
• Vánky E., Stuber G., Willems J., Sjöwall K., Larsson B., Böök K., Ivert T., Peterffy A., Klein E. Importance of MHC antigen expression on solid tumors in the in vitro interaction with autologous blood lymphocytes. Cancer Immunol. Immunother. 1988; 27: 213–222
   PubMedGoogle Scholar
• Austin F. C., Boone C. W. Virus augmentation of the antigenicity of tumor cell extracts. Adv. Cancer Res. 1979; 30: 301–345
   PubMedGoogle Scholar
• Kobayashi H. Viral xenogenization of intact tumor cells. Adv. Cancer Res. 1979; 30: 279–299
   PubMedGoogle Scholar
• Cassel W. A. Viruses in the cause and treatment of cancer, Urol. Oncol., S. D. Graham, Jr. Raven Press, New York 1986; 59–74
   Google Scholar
• Sinkovics J. G., Campos L. T., Kay H. D., Cabiness J. R., Gonzalez E., Loh K. K., Ervin E., Gyorkey E. Immunological studies with human sarcomas: effects of immunization and chemotherapy on cell- and antibody-mediated immune reactions. Immunological Aspects of Neoplasia. Williams and Wilkins, Baltimore, MD 1975; 367–401
   Google Scholar
• Sinkovics J. G., Kay D. H., Thota H. Evaluation of chemoimmunotherapy regimens by in vitro lymphocyte cytotoxicity directed to cultured human tumor cells. Bibliotheca Haematologica 1975; 43: 281–284
   Google Scholar
• Bohle W., Schlag P., Liebrich W., Hohenberger P., Manasterski M., Möller P., Schirrmacher V. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. Cancer 1990; 66: 1517–1523
   PubMed Web of Science ®Google Scholar
• Sinkovics J. G., Thota H., Loh K. K., Gonzalez E., Campos L. X., Romero J. J., Kay H. D., King D. K. Prospectives for immunotherapy for human sarcomas. Cancer Chemotherapy Fundamental Concepts and Recent Advances, 1974. Year Book Medical Publishers, Chicago 1975; 417–443
   Google Scholar
• McMurtrey M. J., Campos L. T., Sinkovics J. G., Romero J. J., Loh K. K., Romsdahl M. M. Chemoimmunotherapy for melanoma: preliminary clinical data and difficulties with in vitro monitoring of tumor-specific immune reactions. Neoplasms of the Skin and Malignant Melanoma, 1975. Year Book Medical Publishers, Chicago 1976; 471–484
   Google Scholar
• Sinkovics J. G., Plager C., McMurtrey M. J., Romero J. J., Romsdahl M. M. (1977) Immunotherapy of human sarcomas, in Management of Primary Bone & Soft Tissue Tumors. 21st Annual Clinical Conference on Cancer. 1976. Year Book Medical Publishers, Chicago, 361–410, The University of Texas M.D. Anderson Hospital, Houston, Texas., Chicago
   Google Scholar
• Sinkovics J. G., Plager C., McMurtrey M. M., Romero J. J., Waldinger R. Active immunization with viral oncolysates integrated in the chemoimmunotherapy of human tumors (melanoma and sarcoma). Seventeenth Interscience Conference on Antimicrobial Agents and Chemotherapy Program and Abstracts. October, 1977, (Abstract #460)
   Google Scholar
• Sinkovics J. G. Viral oncolysates for the immunotherapy of human tumors. Proceedings of the 13th International Congress of Chemotherapy, ViennaAustria, 1983, K. H. Spitzy, K. Karrer. 225: 43–53
   Google Scholar
• Sinkovics J. G. Complete remissions lasting over 3 years in adult patients treated for metastatic sarcomas. Tumor Progression, R. G. Crispen. Elsevier North-Holland, New York, Amsterdam 1980; 315–331
   Google Scholar
• Hoover S. K., Barret S. K., Turk T. M. T., Lee T. -C., Bear H. D. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol. Immunother. 1990; 31: 121–127
   PubMed Web of Science ®Google Scholar
• Berd D., Mastrangelo M. J. Active immunotherapy of human melanoma exploiting the immunopoten-tiating effects of cyclophosphamide. Cancer Invest. 1988; 6: 337–349
   PubMed Web of Science ®Google Scholar
• Sahasrabudhe D. M., de Kernion J. B., Pontes J. E., Ryan D. M., O'Donnell R. W., Marquis D. M., Mudholkar G. S., McCune C. S. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Resp. Mod. 1986; 5: 581–594
   PubMedGoogle Scholar
• Berd D., Mastrangelo M. J. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T cells. Cancer Res. 1988; 48: 1671–1675
   PubMed Web of Science ®Google Scholar
• Braun D. R., Harris J. E. Effects of combination chemotherapy on immunoregulatory cells in peripheral blood of solid tumor cancer patients: correlation with rebound overshoot immune function recovery. Clin. Immunol. Immunopathol. 1981; 20: 193–214
   PubMedGoogle Scholar
• Weisenthal L. M., Dill R. L., Pearson E. C. Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers. J. Natl. Cancer Inst. 1991; 83: 37–41
   PubMedGoogle Scholar
• Sinkovics J. G., Cabiness J. R., Shullenberger C. C. Disappearance after chemotherapy of blocking serum factors as measured in vitro with lymphocytes cytotoxic to tumor cells. Cancer 1972; 30: 1428–1437
   PubMedGoogle Scholar
• Dillman R. O. Rationales for combining chemotherapy and biotherapy in the treatment of cancer. Mol. Biother. 1990; 2: 201–207
   PubMedGoogle Scholar
• Sinkovics J. G., DiSaia R. Y., Rutledge E. N. Tumor immunology and evolution of the placenta. Lancet 1970; 2: 1190–1191
   PubMedGoogle Scholar
• Sinkovics J. G., Plager C., McMurtrey M. J. Chemoimmunotherapy: basic principles and clinical examples, Advances in Medical Oncology, Research and Education, M. Moore. Pergamon Press, Oxford, New York 1979; 6: 121–129
   Google Scholar
• Hoover H. C., Jr., Hanna M. G., Jr. Active Specific Immunotherapy of Colorectal Cancer, Cancer Metastasis. Springer-Verlag, Berlin, Heidelberg 1989; 194–198
   Google Scholar
• Schärfe T., Muller S., Riedmiller H., Jacobi G. H., Hohenfellner R. Immunotherapy of metastasizing renal cell carcinoma. Urol. Int. 1989; 44: 1–4
   PubMedGoogle Scholar
• Tykkä H., Oravisto K. J., Lehtonen T. Active specific immunotherapy of advanced renal cell carcinoma. Eur. Urol. 1978; 4: 250–254
   PubMedGoogle Scholar
• Arroyo P. J., Bash J. A., Wallack M. K. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon a in a murine hepatic metastasis model. Cancer Immunol. Immunother. 1990; 31: 305–311
   PubMed Web of Science ®Google Scholar
• Wallack M. K. Adjuvant therapy of colorectal cancer with vaccinia colon oncolysates. Proc. Am. Soc. Clin. Oncol. 1983; 46, (Abstract #C-178)
   Google Scholar
• Livingston P. O., Takeyama H., Pollack M. S., Houghton A. N., Albino A., Pinsky C. M., Oettgen H. E., Old L. J. Serological responses of melanoma patients to vaccines derived from allogeneic cultures melanoma cells. Int. J. Cancer 1983; 31: 567–575
   PubMed Web of Science ®Google Scholar
• Haspel M. V., McCabe R. P., Pomato N., Janesch N. J., Knowlton J. V., Peters L. C., Hoover H. C., Jr., Hanna M. G., Jr. Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res. 1985; 45: 3951–3961
   PubMed Web of Science ®Google Scholar
• Ehresmann D. W., Hogan R. N. Acceleration of scrapie disease in mice by an adenovirus. Intervirology 1986; 25: 103–110
   PubMed Web of Science ®Google Scholar
• McChesney M. B., Oldstone M. B. A. Viruses perturb lymphocyte functions: selected principles characterizing virus-induced immunosuppression. Ann. Rev. Immunol. 1987; 5: 279–304
   PubMed Web of Science ®Google Scholar
• Leist T. P., Rüedi E., Zinkernagel R. M. Virus-triggered immune suppression in mice caused by virus specific cytotoxic T cells. J. Exp. Med. 1988; 167: 1749–1754
   PubMedGoogle Scholar
• Confer D. L., Vercellotti G. M., Kotasek D., Goodman J. L., Ochoa A., Jacob H. S. Herpes simplex virus-infected cells disarm killer lymphocytes. Proc. Natl. Acad. Sci. USA 1990; 87: 3609–3613
   PubMedGoogle Scholar
• Oldstone M. B. A. Viral persistence. Cell 1989; 56: 517–520
   PubMed Web of Science ®Google Scholar
• Sinkovics J. G., Howe C. D. Superinfection of tumors with viruses. Experientia 1969; 25: 733–734
   PubMedGoogle Scholar
• Sinkovics J. G. Cytotoxic lymphocytes. Ann. Clin. Lab. Sci. 1986; 16: 488–496
   PubMedGoogle Scholar
• Sinkovics J. G. Oncolytic viruses and viral oncolysates: new ideas. 15th International Cancer Congress, Hamburg, August 16-22, Supplement to J. Cancer Res. Clin. Oncol. 116(Part II), 1094, 1990. (Abstract #20.01.07)
   Google Scholar
• Martuza R. L., Malick A., Markert J. M., Ruffner K. L., Coen D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 354–356
   Google Scholar
• Hinder E., Schmidt A., Gong J-H., Bender A., Sprenger H., Nain M., Gemsa D. Influenza A virus infects macrophages and stimulates release of tumor necrosis factor alpha. Pathology 1991; 59: 227–231
   Google Scholar